The 2021 fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System formally recognizes four spinal entities: spinal ependymoma, spinal ependymoma with MYCN amplification, spinal subependymoma, and spinal myxopapillary ependymoma. Diagnosis is no longer a matter of histology alone. Instead, clinicians must integrate the anatomical compartment, the microscopic appearance of the tumor, and its molecular signature, most often assessed through DNA methylation profiling. That shift matters because the subtypes behave very differently. Myxopapillary ependymomas, for example, were upgraded from grade 1 to grade 2 after clinicians realized that incompletely removed tumors, once watched passively, could recur with spread through the subarachnoid space, a complication that typically forces craniospinal irradiation and carries substantial morbidity.

Pediatric-specific molecular data are beginning to sharpen this picture. In the HIT-MED spinal cohort of 83 patients aged 22 or younger, methylation classes broke down as 63 percent myxopapillary, 33 percent conventional spinal ependymoma, and 4 percent MYCN-amplified. Strikingly, within this pediatric population the molecular class did not clearly separate risk levels between the two most common groups; instead, the extent of surgical resection and the WHO grade remained the dominant determinants of progression-free survival. Molecular profiling, in other words, refines biological classification, but for most children the scalpel and the microscope still tell the most important part of the story.

The exception is the MYCN-amplified subtype, which the review describes as one of the most aggressive entities in the entire ependymoma family. These tumors tend to relapse early, typically within about 2.3 years, and can prove fatal despite aggressive multimodal treatment regardless of the age at diagnosis. Identifying MYCN amplification therefore has immediate clinical consequences: high-risk counseling, intensified craniospinal surveillance, and consideration of clinical trials or novel therapeutics. The authors argue that every spinal ependymoma specimen should undergo reflex testing for MYCN amplification alongside formal WHO 2021 grading and, where available, methylation profiling. Even the ostensibly indolent myxopapillary tumors carry sobering long-term statistics, with a 10-year progression-free survival of roughly 59 percent in mixed-age datasets, and within pediatric myxopapillary disease, methylation subtype B showed a trend toward better five-year progression-free survival than subtype A, 86 percent versus 56 percent, though the difference has not reached statistical significance.

Clinically, these tumors announce themselves quietly. Adults and older children typically report progressive sensory disturbance, gait imbalance, weakness, axial back pain, or radicular pain, and most patients are still ambulatory at diagnosis. The insidious tempo, however, often means the tumor has extended over multiple spinal segments by the time imaging is obtained. In preverbal children the presentation can be maddeningly nonspecific: torticollis, regression of motor milestones, refusal to walk or crawl, or simple irritability, signs easily misattributed to musculoskeletal or developmental causes. The review stresses that any suspicion demands gadolinium-enhanced MRI of the entire neuraxis, including the brain, because drop metastases occur in a minority of patients and missing them leads to under-staging and inadequate adjuvant planning.

On imaging, the intramedullary subtypes typically show symmetric cord expansion, well-demarcated margins, contrast enhancement, polar cysts, and syringomyelia in 40 to 70 percent of cases. A rim of hemosiderin at the tumor poles, the so-called cap sign, hints at a distinct gliotic plane that surgeons can exploit for dissection. MYCN amplification itself cannot be seen radiographically, but irregular margins, infiltrative extension, multifocal nodularity, or leptomeningeal enhancement should raise suspicion for high-risk molecular disease. Myxopapillary tumors behave differently, arising extramedullary at the filum terminale with a lobulated, avidly enhancing morphology that displaces rather than infiltrates neighboring nerve roots.

Surgery sits at the center of management, and the review frames every operative decision along three fronts: whether gross total resection is anatomically feasible, what functional neurological risks it carries, and what the biological risk of recurrence or dissemination happens to be. Gross total resection is the most consistent modifiable predictor of progression-free survival, with contemporary series reporting rates of roughly 72 to 83 percent. Continuous multimodal intraoperative neuromonitoring, combining somatosensory evoked potentials, transcranial motor evoked potentials, and D-wave recording, allows real-time assessment of the dorsal columns and corticospinal tract, and a sustained deterioration in motor potentials or a significant D-wave drop strongly predicts permanent motor deficit. When signals fail irreversibly, a deliberate subtotal resection may be the wiser course, and early postoperative MRI within 24 to 48 hours guides whether a second-look operation should precede any adjuvant therapy. For myxopapillary lesions, meticulous capsule preservation is paramount, because capsular violation is associated with local recurrence, cerebrospinal fluid dissemination, and the need for radiotherapy; en bloc resection is preferred when technically feasible.

In children, the spine itself becomes a battleground. Postoperative deformity is arguably the most important surgical morbidity in this population, and the data are stark: in one series of 161 children, 27 percent eventually required fusion, with risk rising sharply in those under 13, those with preoperative scoliosis, tumor-associated syrinx, thoracolumbar junction involvement, or each additional resection. Another study found deformity in 38 percent of children before surgery and 69 percent afterward, even when laminoplasty was used throughout, underscoring that tumor biology and preoperative status drive much of the risk. Neither laminoplasty nor laminectomy reliably prevents kyphosis, and instrumented fusion, while stabilizing, permanently sacrifices motion and growth potential and can degrade the quality of the lifelong surveillance MRI these patients need. Radiation adds its own age-dependent hazard: a comprehensive PENTEC review found clinically significant scoliosis at vertebral doses as low as 15 Gy in infants under two, with rates exceeding 30 percent above 20 Gy in children aged two to six, thresholds substantially below the 45 to 59.4 Gy focal doses typically prescribed.

Adjuvant therapy follows a risk-adapted logic. After gross total resection of a grade 2 spinal ependymoma, most contemporary evidence supports surveillance without routine radiotherapy, since a clear benefit has not been consistently demonstrated. After subtotal resection or biopsy, focal conformal radiotherapy is recommended because incomplete resection consistently predicts inferior progression-free survival. Grade 3 tumors receive focal radiotherapy regardless of resection extent, and craniospinal irradiation is considered when dissemination is present or suspected. For myxopapillary tumors the role of postoperative radiotherapy remains genuinely contested, with some retrospective series, including pediatric cohorts, suggesting improved control even after complete resection, particularly with dose escalation above 50.4 Gy or when high-risk features exist, while other adult-dominant datasets support observation alone. A recent multi-institutional pediatric and young adult series of high-risk myxopapillary disease reported five-year overall survival of 100 percent and progression-free survival of 60.8 percent, but patients still relapsed outside the treated field and intracranially, arguing for vigilance beyond the radiation volume rather than dose escalation alone. Chemotherapy, meanwhile, has no established frontline role; it is reserved for recurrent or disseminated disease, clinical trials, or as a deliberate strategy to defer radiotherapy in infants, an approach validated for intracranial ependymoma but never formally studied in the spine.

The review’s most candid contribution may be its systematic accounting of what medicine does not know. Nearly every management domain, from radiotherapy dosing and timing to the value of molecular stratification beyond MYCN, rests on adult or mixed-age retrospective cohorts, and no prospective pediatric-specific data address whether current thresholds should differ for a growing child. Local recurrence remains the dominant failure pattern even after complete resection, and craniospinal dissemination can appear years later, which is why the authors recommend lifelong MRI surveillance for every patient, with intensified brain and full-neuraxis imaging for those with dissemination or high-risk subtypes. For isolated recurrences, repeat maximal safe resection remains the mainstay, followed by focal radiotherapy in radiation-naive patients, though cumulative dose tolerance to the spinal cord and the specter of radiation-induced deformity weigh heavily in children who face a far longer horizon of potential exposure. The path forward, the authors conclude, requires prospective multicenter studies, validated molecular risk models, and novel systemic therapies for the aggressive subtypes, so that the next generation of children with spinal ependymoma can be treated on evidence of their own rather than borrowed from adults.

Subject of Research: Molecular classification and management of pediatric spinal ependymoma

Article Title: Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)

Article References: Price, A. M., Fredricks, N. S., Koutsouras, G., Vallejo, F. A., Bonfield, C., Pastakia, D. J., Luo, L. Y., Boop, F., Ramaswamy, V., & Dewan, M. C. (2026). Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments). Journal of Neuro-Oncology, 180(1), Article 6. https://doi.org/10.1007/s11060-026-05816-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05816-9

Keywords: spinal ependymoma, pediatric neuro-oncology, MYCN amplification, myxopapillary ependymoma, WHO CNS5 classification, gross total resection, intraoperative neuromonitoring, adjuvant radiotherapy, spinal deformity, DNA methylation profiling, craniospinal irradiation, lifelong surveillance